Progress of Refocus Group’s Clinical Trial

Mike Judy, CEO, Refocus Group, a company dedicated to non-invasive surgical solutions for presbyopia, presented early data on the its ongoing clinical trial. The firm hopes to secure FDA approval in early 2018.